NDA 021723 · Cp Pharms
Lyrica
Pregabalin · Oral
Last checked: Nov 20, 2026Latest source record: Dec 30, 2004 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2004
Dec 30, 2004
Approved uses
1
Original approval plus efficacy supplements
Registered trials
564
150 Phase 3, 40 recruiting
FAERS reports
273,908
183,607 serious, 22,698 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 30, 2004 Original approval · Type 6 - New Indication (no longer used) Healthcare Professional SheetReviewLetter
8 products under this application
- LYRICA · PREGABALIN 300MG · CAPSULE, ORAL · Prescription
- LYRICA · PREGABALIN 200MG · CAPSULE, ORAL · Prescription
- LYRICA · PREGABALIN 100MG · CAPSULE, ORAL · Prescription
- LYRICA · PREGABALIN 50MG · CAPSULE, ORAL · Prescription
- LYRICA · PREGABALIN 225MG · CAPSULE, ORAL · Prescription
- LYRICA · PREGABALIN 150MG · CAPSULE, ORAL · Prescription
- LYRICA · PREGABALIN 75MG · CAPSULE, ORAL · Prescription
- LYRICA · PREGABALIN 25MG · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Pregabalin" as an intervention, any sponsor and status, largest first.
- Quality Improvement and Practice Based Research in Neurology Using the EMREnrolling by invitation
Endeavor HealthAcademic, hospital or other
NCT02670161 · 3,300 participants (planned) · Start May 2016 · Primary completion Dec 2026
Drug: Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description) · For: Brain Tumors; Epilepsy; Migraine and 7 more
Sites: Evanston, Illinois
- MAST Trial: Multi-modal Analgesic Strategies in TraumaPivotal-lookingCompleted
The University of Texas Health Science Center, HoustonAcademic, hospital or other
NCT03472469 · 1,561 participants · Start Apr 2, 2018 · Primary completion Jul 3, 2019
Drug: Acetaminophen IV/PO; Acetaminophen PO and 9 more · For: Nonspecific Pain Post Traumatic Injury
Sites: Houston, Texas
- Treatment of Pain Associated With FibromyalgiaPivotal-lookingCompleted
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT02187471 · 1,301 participants · Start Jan 16, 2015 · Primary completion Jan 6, 2017
Drug: DS-5565; Pregabalin and 2 more · For: Pain Associated With Fibromyalgia
Sites: Birmingham, Alabama; Huntsville, Alabama; Phoenix, Arizona · 154 sites in all
- Treatment of Pain Associated With FibromyalgiaPivotal-lookingCompleted
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT02146430 · 1,293 participants · Start Oct 27, 2014 · Primary completion Jul 14, 2016
Drug: DS-5565; Pregabalin and 2 more · For: Pain Associated With Fibromyalgia
Sites: Glendale, Arizona; Phoenix, Arizona; Anaheim, California · 165 sites in all
- Treatment of Pain Associated With FibromyalgiaPivotal-lookingCompleted
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT02187159 · 1,270 participants · Start Nov 2014 · Primary completion Jul 7, 2016
Drug: DS-5565; Pregabalin and 2 more · For: Pain Associated With Fibromyalgia
Sites: Mobile, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 176 sites in all
- The Efficacy and Safety of Pregabalin and Crisugabalin in Patients With FibromyalgiaPivotal-lookingRecruiting
Beijing Tiantan HospitalAcademic, hospital or other
NCT07196657 · 1,116 participants (planned) · Start Sep 30, 2025 · Primary completion Jun 30, 2027
Drug: Pregabalin; Crisugabalin · For: Fibromyalgia; Pregabalin; Pain
Sites: Beijing, China
- Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral NeuropathyPivotal-lookingRecruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT06628908 · 1,100 participants (planned) · Start Oct 1, 2024 · Primary completion May 31, 2027
Drug: Suzetrigine; Placebo (matched to SUZ) and 2 more · For: Diabetic Peripheral Neuropathic Pain
Sites: Anniston, Alabama; Birmingham, Alabama; Daphne, Alabama · 76 sites in all
- Safety and Efficacy Study of Pregabalin in FibromyalgiaPivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT00151489 · 1,020 participants · Start Apr 2005
Drug: pregabalin; placebo · For: Fibromyalgia
Sites: Anniston, Alabama; Birmingham, Alabama; Calera, Alabama · 109 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective27,200
- pain26,508
- fatigue15,853
- dizziness15,031
- nausea14,720
- off label use14,004
- headache13,242
- malaise12,999
- somnolence11,958
- weight increased11,711
- pain in extremity11,488
- fall11,138
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 5 |
| 2005 | 351 |
| 2006 | 4,998 |
| 2007 | 2,871 |
| 2008 | 3,560 |
| 2009 | 3,001 |
| 2010 | 13,566 |
| 2011 | 6,904 |
| 2012 | 13,074 |
| 2013 | 14,156 |
| 2014 | 16,247 |
| 2015 | 18,634 |
| 2016 | 19,912 |
| 2017 | 18,062 |
| 2018 | 20,542 |
| 2019 | 22,875 |
| 2020 | 18,930 |
| 2021 | 14,842 |
| 2022 | 13,309 |
| 2023 | 11,934 |
| 2024 | 13,545 |
| 2025 | 13,013 |
| 2026 | 9,577 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Lyrica (Pregabalin)
2024 spending
$62.0M
Beneficiaries
11,809
65,724 claims
Per beneficiary
$5,253
$9.67 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $147,354,969 |
| 2021 | $90,904,463 |
| 2022 | $78,715,397 |
| 2023 | $71,720,875 |
| 2024 | $62,035,504 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomised crossover trial.
Tesfaye S, Sloan G, Petrie J, et al. · Lancet 2022 · Multicenter Study, Randomized Controlled Trial
- Pregabalin for neuropathic pain in adults.
Derry S, Bell RF, Straube S, et al. · Cochrane Database Syst Rev 2019 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Gabapentin and pregabalin in bipolar disorder, anxiety states, and insomnia: Systematic review, meta-analysis, and rationale.
Hong JSW, Atkinson LZ, Al-Juffali N, et al. · Mol Psychiatry 2022 · Meta-Analysis, Systematic Review
- A systematic review and meta-analysis of the effectiveness and adverse events of gabapentin and pregabalin for sciatica pain.
Giménez-Campos MS, Pimenta-Fermisson-Ramos P, Díaz-Cambronero JI, et al. · Aten Primaria 2022 · Meta-Analysis, Systematic Review
- The safety and efficacy of gabapentinoids in the management of neuropathic pain: a systematic review with meta-analysis of randomised controlled trials.
Meaadi J, Obara I, Eldabe S, et al. · Int J Clin Pharm 2023 · Meta-Analysis, Systematic Review
- Anticonvulsants for fibromyalgia.
Üçeyler N, Sommer C, Walitt B, et al. · Cochrane Database Syst Rev 2013 · Meta-Analysis, Systematic Review
Sponsor: Cp Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.